SAN DIEGO, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( www.apricusbio.com), today announced a change in the Company's presentation time at the 2013 Stifel Nicolaus Healthcare Conference, being held at The Four Seasons Hotel in Boston, MA. Richard Pascoe, Chief Executive Officer, will present on Wednesday, September 11, 2013 at 8:00 a.m. Eastern Time. The presentation will be webcast and accessible to the public online at http://www.veracast.com/webcasts/stifel/healthcare2013/23103651508.cfm or via the Company's website at http://www.apricusbio.com. A replay will be available for 30 days after the presentation. About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros ®, for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox ®, the Company's product candidate for the treatment of female sexual interest and arousal disorder, has successfully completed a nearly 400-subject proof-of-concept study. For further information on Apricus Bio, visit http://www.apricusbio.com.
CONTACT: Apricus Bio Investor Relations: David Pitts or Lourdes Catala Argot Partners 212-600-1902 email@example.com firstname.lastname@example.org